Michael D. Prados

TL;DR: These results in GBM were comparable to other phase II GBM trials and thus do not represent a therapeutic advance in the treatment of GBM, but results are consistent with continued investigation of thymidine in combination with chemotherapeutic agents for high-grade glioma and other malignant diseases.

TL;DR: The maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), was determined to be 500 mg/m2 and it was confirmed that concomitant administration of EIAEDs increases irinOTecan clearance and influences SN-38 disposition.

TL;DR: Considering only patients with GTR, age at diagnosis continued to be a statistically significant prognostic factor and patients treated during surgically based phase II studies should be matched with a historical control group restricted to patients with similar pretreatment variables, including GTR.

TL;DR: The overall high rate of recurrence leads us to recommend radiation to doses of 45 to 54 Gy for all patients who do not have gross total resections, and long, close follow-up, and to recommend maximal excision while avoiding surgical morbidity.